Clinical Evaluation of the Effect of Aficamten on QT/QTc Interval in Healthy Participants

Clinical Evaluation of the Effect of Aficamten on QT/QTc Interval in Healthy Participants

ABSTRACT Aficamten is a next‐in‐class, small‐molecule, cardiac myosin inhibitor in development for treating hypertrophic cardiomyopathy (HCM). This 2‐part study evaluated aficamten's impact on QTc interval in healthy participants. Part A (n = 10) was an open‐label study to find the appropriate...

Full description

Saved in:
Bibliographic Details
Main Authors: Neha Maharao, Donghong Xu, Tyrell J. Simkins, Owen Bowles, Genzhou Liu, Youcef Benattia, Adrienne Griffith, Stephen B. Heitner, Stuart Kupfer, Polina German
Format: Article
Language:English
Published: Wiley 2025-04-01
Series:Clinical and Translational Science
Subjects:
cardiovascular disease
phase 1
QT
QTc interval
safety
Online Access:https://doi.org/10.1111/cts.70218
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1111/cts.70218

Similar Items